[
  {
    "ts": "2026-02-24T04:20:18+00:00",
    "headline": "Truist Raises Cigna (CI) Price Target to $350, Sees Clearer Growth Outlook after Q4",
    "summary": "The Cigna Group (NYSE:CI) is included among the 13 Best Strong Buy Dividend Stocks to Invest in. On February 17, Truist raised its price recommendation on The Cigna Group (NYSE:CI) to $350 from $320. The firm reiterated a Buy rating on the stock. The analyst updated the firm’s model following the company’s Q4 results and its […]",
    "url": "https://finance.yahoo.com/news/truist-raises-cigna-ci-price-042018156.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "04bc2bf2-fa1e-3f93-8c2d-c21ba9c22410",
      "content": {
        "id": "04bc2bf2-fa1e-3f93-8c2d-c21ba9c22410",
        "contentType": "STORY",
        "title": "Truist Raises Cigna (CI) Price Target to $350, Sees Clearer Growth Outlook after Q4",
        "description": "",
        "summary": "The Cigna Group (NYSE:CI) is included among the 13 Best Strong Buy Dividend Stocks to Invest in. On February 17, Truist raised its price recommendation on The Cigna Group (NYSE:CI) to $350 from $320. The firm reiterated a Buy rating on the stock. The analyst updated the firm’s model following the company’s Q4 results and its […]",
        "pubDate": "2026-02-24T04:20:18Z",
        "displayTime": "2026-02-24T04:20:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f3cab3417a0914d8342aabaa68eb8ec2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Truist Raises Cigna (CI) Price Target to $350, Sees Clearer Growth Outlook after Q4",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Pd6lMu6k0IapJWyjyW4vdQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f3cab3417a0914d8342aabaa68eb8ec2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OlyAL6nINgNtlVWehXM8Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f3cab3417a0914d8342aabaa68eb8ec2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/truist-raises-cigna-ci-price-042018156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/truist-raises-cigna-ci-price-042018156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CI"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T06:06:12+00:00",
    "headline": "How The Story On Harmony Biosciences (HRMY) Is Shifting With Wakix Legal And Generic Risks",
    "summary": "Harmony Biosciences Holdings is back in focus after a modest lift in fair value estimates, from about US$46.45 to roughly US$47.30 per share. That small adjustment sits against a split analyst backdrop, with more supportive views anchored to Wakix cash flow assumptions and cautious voices concentrating on legal risks and the timing of potential generic entry. As you read on, you will see how these competing views shape the story and what to watch to stay on top of the evolving...",
    "url": "https://finance.yahoo.com/news/story-harmony-biosciences-hrmy-shifting-060612053.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2cfb45b9-f51e-3fb3-9184-0b44b0ab0735",
      "content": {
        "id": "2cfb45b9-f51e-3fb3-9184-0b44b0ab0735",
        "contentType": "STORY",
        "title": "How The Story On Harmony Biosciences (HRMY) Is Shifting With Wakix Legal And Generic Risks",
        "description": "",
        "summary": "Harmony Biosciences Holdings is back in focus after a modest lift in fair value estimates, from about US$46.45 to roughly US$47.30 per share. That small adjustment sits against a split analyst backdrop, with more supportive views anchored to Wakix cash flow assumptions and cautious voices concentrating on legal risks and the timing of potential generic entry. As you read on, you will see how these competing views shape the story and what to watch to stay on top of the evolving...",
        "pubDate": "2026-02-24T06:06:12Z",
        "displayTime": "2026-02-24T06:06:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/story-harmony-biosciences-hrmy-shifting-060612053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/story-harmony-biosciences-hrmy-shifting-060612053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HRMY"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T11:40:00+00:00",
    "headline": "Truist Could Soar If These 2 Things Go Right",
    "summary": "Keep an eye on the bank's revenues, rising margins, and stock buybacks in 2026.",
    "url": "https://www.fool.com/investing/2026/02/24/truist-financial-could-soar-if-these-things-go-rig/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a5c71020-bf58-3e2c-8fd7-c089649c3421",
      "content": {
        "id": "a5c71020-bf58-3e2c-8fd7-c089649c3421",
        "contentType": "STORY",
        "title": "Truist Could Soar If These 2 Things Go Right",
        "description": "",
        "summary": "Keep an eye on the bank's revenues, rising margins, and stock buybacks in 2026.",
        "pubDate": "2026-02-24T11:40:00Z",
        "displayTime": "2026-02-24T11:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/48ac00a7689574327666f0f070547997",
          "originalWidth": 1200,
          "originalHeight": 801,
          "caption": "Hands holding100 dollar bills.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6V9UKL6NWJCsN5P1zClUDQ--~B/aD04MDE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/48ac00a7689574327666f0f070547997.cf.webp",
              "width": 1200,
              "height": 801,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/je6HXhI9thTi0wmwbdlt2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/48ac00a7689574327666f0f070547997.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/24/truist-financial-could-soar-if-these-things-go-rig/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/truist-could-soar-2-things-114000321.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]